Nevirapine Accord Healthcare (Nevirapine)

Nevirapine belongs to the non‑nucleoside reverse transcriptase inhibitor (NNRTI) class. It binds to a specific non‑active site on the HIV‑1 reverse transcriptase enzyme, causing a conformational change that blocks the enzyme’s ability to transcribe viral RNA into DNA, thereby interrupting the HIV replication cycle.

The dosing regimen for nevirapine is individualized by the prescribing clinician based on the patient’s age, weight, treatment history, and co‑medications. Healthcare providers follow established guidelines to determine the appropriate starting dose and any necessary adjustments during therapy.

The safety of nevirapine in pregnancy and lactation has not been definitively established. Clinicians must weigh the potential benefits of viral suppression against any possible risks to the fetus or infant, and consider alternative regimens when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Both nevirapine and efavirenz are NNRTIs, but they differ in pharmacokinetic profiles and side‑effect spectra. Nevirapine is often associated with rash and hepatotoxicity, while efavirenz commonly causes central nervous system effects. Choice of agent depends on patient tolerance, comorbidities, drug‑interaction potential, and clinician preference.

Nevirapine tablets should be stored at ambient temperature, preferably below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and avoid storing in high‑humidity environments.

Nevirapine is administered orally as a tablet, usually taken with food or a meal to improve tolerability. The exact dosing schedule, including the number of tablets and timing, is determined by the prescribing physician as part of a combination antiretroviral regimen.

The most serious adverse reactions include severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, and potentially life‑threatening hepatotoxicity. Prompt medical evaluation is required if patients develop rash, jaundice, fever, or unexplained fatigue.

Nevirapine is contraindicated in individuals with a known hypersensitivity to nevirapine or any other NNRTI, and in patients with pre‑existing moderate to severe liver disease. Caution is also advised for patients with a history of severe rash or those receiving certain interacting medications.